Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that the initial clinical data from the safety study for Symphony™ was presented by Renzo Cecere, M.D., FRCSC, FACS, Associate Professor of Surgery at McGill University, during the late-breaking clinical trials session at the Society of Thoracic Surgeons (STS) 2012 Annual Meeting in Fort Lauderdale, Florida.
The presentation, "Initial Safety Trial of an Implantable, Synchronous, Partial Circulatory Support Device: Symphony™," discussed the initial clinical data from the Symphony safety trial being conducted outside of the U.S., and was presented during one of the four late-breaking clinical trials sessions at the STS 2012 Annual Meeting.
The presentation included analysis of the initial first-in-man experience, originally announced in December 2011, which demonstrated feasibility of the synchronized, implantable heart pump called Symphony. The analysis indicated a marked improvement in cardiac output, improved renal function, short intensive care unit (ICU) stay and early patient mobility post implant.
"The concept of a minimally invasive implantable pump for patients in chronic heart failure, coupled with the ability to remodel the heart, is unique and groundbreaking and we are very pleased with the initial findings of Symphony," said Dr. Cecere.
DASH diet may lower the risk of cardiovascular disease in breast cancer survivors